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A Case Report of Potential MINOCA in CAR-T
Danielle Verghese, PGY-1, Adam Binder, MD, Colin Thomas, MD
INTRODUCTION
The discovery and application of Chimeric Antigen 
Receptor T-Cell Therapy (CAR-T) has marked a new era 
in cancer treatment. CAR-T is a novel therapy with a 
relatively small treatment population, and we have yet 
to identify the full spectrum of its adverse effects.1 
There are well-established approaches to the most 
common adverse effects, principally cytokine release 
syndrome (CRS), but there is limited literature discussing 
the nature of cardiotoxicity in CAR-T, much less its 
mechanism or management.2,3 This case study 
discusses the development of myocardial infarction 
with no obstructive coronary atherosclerosis (MINOCA) 
in a patient treated with CAR-T.
CASE PRESENTATION
A 48-year-old man with a history of Stage IV Diffuse 
Large B-Cell Lymphoma refractory to R-CHOP 
alternating with high-dose methotrexate and cytarabine, 
craniospinal irradiation, and haploidentical stem cell 
transplant, underwent CD 19-directed CAR-T. His 
post-treatment course was complicated by marrow 
aplasia and infection, but he ultimately responded to 
therapy and achieved complete remission. 
Five months after undergoing CAR-T, the patient 
presented with persistent malaise and vague abdominal 
pain. Initial assessment found him to be cachectic and 
frail, and he was admitted for further investigation of 
failure to thrive (FTT). An extensive workup of endocrine, 
metabolic, and infectious causes of FTT was unrevealing. 
Labs showed stable neutropenia (ANC 0.4) and anemia 
(Hgb 9.7) with no evidence of adrenal insufficiency, 
thyroid dysfunction, vitamin deficiencies, nor bacterial, 
viral, or fungal infections. EGD did not reveal any 
significant gastrointestinal pathology, only patches of 
chronic, mild inflammation. 
On the sixth day of hospitalization, the patient reported 
left shoulder pain. Telemetry showed an acute increase 
in heart rate, from a baseline sinus tachycardia of 100-110 
bpm to 130-140 bpm. EKG revealed new inferior ST 
segment elevations. Echocardiography identified newly 
depressed ejection fraction (45%) and basal to 
mid-anterior and anteroseptal wall motion abnormalities, 
where previous studies had shown normal EF and no 
segmental wall motion abnormalities. High-sensitivity 
troponins were elevated and continued to rise from – 
344 ng/L followed by 366 ng/L in the setting of normal 
renal function. Subsequent cardiac catheterization 
revealed no obstructive coronary artery disease. 
Altogether, the evidence for myocardial injury in the 
absence of obstructive coronary artery disease 
culminated in a diagnosis of MINOCA.
A multi-disciplinary team including Cardiology and 
Hematology-Oncology reviewed possible etiologies of 
cardiac injury. Although the patient had previously 
received doxorubicin chemotherapy (total of 229 mg, 20 
months prior to this admission), the acute onset of ST 
elevations and dynamic troponins were atypical for 
anthracycline-induced cardiomyopathy.4 Similarly, the 
presentation was not typical for stress-induced cardio-
myopathy, especially in the absence of an acute trigge.5 
The constellation of cardiac findings was attributed to 
myocarditis, but the underlying cause remained unclear. 
The patient was not taking any medications commonly 
associated with myocarditis. Infectious workup was 
negative including blood cultures, urine cultures, 
influenza A and B, respiratory pathogen panel, EBV, CMV, 
tuberculosis and aspergillus testing. Of note, testing for 
coxsackie A and B, HIV, and HSV was not performed. 
Previous reports have posited a CRS-mediated 
mechanism of cardiac injury in CAR-T, but CRS typically 
peaks days after treatment, and would be uncommon 
months after CAR-T infusion.6 Another proposed 
mechanism considers off-target cross-reactivity, leading 
to an autoimmune myocarditis.6 The next best steps to 
workup myocarditis would have been further infectious 
testing, cardiac MRI, endomyocardial biopsy, but these 
were deferred as the patient was high-risk for invasive 
procedures and the findings were unlikely to change 
clinical management.
Besides myocarditis, other etiologies of MINOCA include 
coronary vasospasm, coronary microvascular 
dysfunction, and thrombophilia7. These were not further 
investigated during the patient’s hospitalization.  
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DISCUSSION
CAR-T is a novel therapy with a relatively small treatment 
population, and we have yet to uncover the full spectrum 
of its effects. This case illustrates the potential for MINOCA 
as a result of CAR-T-induced myocarditis. Other possible 
etiologies of MINOCA include coronary vasospasm and 
coronary microvascular dysfunction, but there is no 
available literature on these pathologies in CAR-T. 
Identifying similar cases will allow for further character-
ization of susceptible patient populations, underlying 
mechanisms, and preventative strategies. 
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